Sohlh2 inhibits ovarian cancer cell proliferation by upregulation of p21 and downregulation of cyclin D1

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages 1863-1871

  Zhang, Haiyu ^a   Zhang, Xiaoli ^a   Ji, Shufang ^a   Hao, Chunyan ^a   Mu, Yulan ^b   Sun, Jinhao ^a   Hao, Jing ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Cell proliferation; Cyclin D1; Ovarian cancer; p21; sohlh2

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BETA ACTIN; BROXURIDINE; CYCLIN A; CYCLIN D1; CYCLIN E; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P21; PROTEIN P27; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOHLH2; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; SOHLH2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BENIGN TUMOR; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MOUSE; MTT ASSAY; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; OVIDUCT; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION INITIATION SITE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; UTERINE TUBE; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CELL CYCLE; COMPARATIVE STUDY; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NEOPLASM; NONOBESE DIABETIC MOUSE; OVARY; PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FALLOPIAN TUBES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905715064     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu113     Document Type: Article

References (36)

1. Dubeau, L. (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol, 9, 1191-7.
2. Cannistra, S.A. (2004) Cancer of the ovary. N Engl J Med, 351, 2519-29.
3. Bray, F., et al. (2005) Ovarian cancer in Europe:Cross-sectional trends in incidence and mortality in 28 countries,1953-2000. Int J Cancer, 113, 977-990.
4. Jemal, A., et al. (2010) Cancer statistics. CA Cancer J Clin, 60, 277-300.
5. Kim, A., et al. (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res, 31, 14-22.
6. Perren, T.J., et al. (2011) ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 365, 2484-96.
7. Fong, P.C., et al. (2010) Poly(ADP)-ribose polymerase inhibition:frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol, 28, 2512-2519.
8. Ballow, D.J., et al. (2006) Sohlh2 is a germ cell-specific bHLH transcription factor. Gene Expr Pattern, 6, 1014-1018.
9. Sun, H., et al. (2007). bHLH-Orange Transcription Factors in Development and Cancer. Transl Oncogenomics, 2, 107-20.
10. Hao, J., et al. (2008) Sohlh2 knockout mice are male-sterile because of degeneration of differentiating type A spermatogonia. Stem Cells, 26(6), 1587-1597.
11. Toyoda, S., et al. (2009) Sohlh2 affects differentiation of KIT positive oocytes and spermatogonia. Dev Biol, 325(1), 238-248.
12. Suzuki, H., et al. (2012) SOHLH1 and SOHLH2 coordinate spermatogonial differentiation. Dev Biol, 361(2), 301-312.
13. Su, A.I., et al.(2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A, 101(16), 6062-7.
14. Lukk, M., et al. (2010) A global map of human gene expression. Nat Biotechnol, 28(4), 322-4.
15. Han, C.P., et al. (2009) Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol, 22, 797-806.
16. Kamoi, S., et al. (2002) Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol, 21, 217-23.
17. Rodriguez-Ubreva, J., et al. (2014) Chromatin immunoprecipitation.Methods Mol Biol, 1094, 309-18.
18. Kurman, R.J., et al. (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, 34, 433-43.
19. Woloszynska-Read, A., et al. (2011) Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res, 17(8), 2170-80.
20. Bhawal, U.K., et al. (2011) Basic helix-loop-helix transcription factor DEC1 negatively regulates cyclin D1. J Pathol, 224(3), 420-9.
21. Pagliuca, A., et al. (2000) Class A helix-loop-helix proteins are positive regulators of several cyclin-dependent kinase inhibitors' promoter activity and negatively affect cell growth. Cancer Res, 60, 1376-1382.
22. Cmielova, J., et al. (2011) p21Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J Cell Biochem, 112(12), 3502-6.
23. Liu, S., et al. (2003) Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat, 6(4),183-95.
24. Ju, Z., et al. (2006) A dual role of p21 in stem cell aging. Ann NY Acad Sci, 1100, 333-344.
25. Cazzalini, O., et al. (2010) Multiple roles of the cell cycle inhibitor p21 (CDKN1A) in the DNA damage response. Mutat Res, 704,12-20.
26. Warfel, N.A., et al. (2013) p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol, 25(1), 52-8.
27. Prall, O.W., et al. (1998) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol, 18, 4499-4508.
28. Motokura, T., et al. (1991) A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature, 350(6318), 512-515.
29. Oesterreich, S., et al. (2003) Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res, 63(17), 5203-5208.
30. Ma, X.J., et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA, 100, 5974-5979.
31. Wang, T.C., et al. (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature, 369(6482), 669-671.
32. Musgrove, E.A., et al. (1994) Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA, 91(17), 8022-8026.
33. Quelle, D.E., et al. (1993) Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev, 7(8), 1559-1571.
34. Baldin, V., et al. (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev, 7(5), 812-821.
35. Gonzalez-Mariscal, L., et al. (2009) The tight junction protein ZO-2 blocks cell cycle progression and inhibits cyclin D1 expression. Ann N Y Acad Sci, 1165, 121-5.
36. Huerta, M., et al. (2007) CyclinD1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc. Mol Biol Cell, 18, 4826-4836.